KR102714702B1 - 항-pd-1 항체를 사용하여 종양을 치료하는 방법 - Google Patents

항-pd-1 항체를 사용하여 종양을 치료하는 방법 Download PDF

Info

Publication number
KR102714702B1
KR102714702B1 KR1020197038639A KR20197038639A KR102714702B1 KR 102714702 B1 KR102714702 B1 KR 102714702B1 KR 1020197038639 A KR1020197038639 A KR 1020197038639A KR 20197038639 A KR20197038639 A KR 20197038639A KR 102714702 B1 KR102714702 B1 KR 102714702B1
Authority
KR
South Korea
Prior art keywords
tumor
antibody
subject
stk11
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197038639A
Other languages
English (en)
Korean (ko)
Other versions
KR20200014363A (ko
Inventor
로빈 에드워즈
윌리엄 제이. 기스
다니엘 엠. 그리나월트
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Priority to KR1020247032911A priority Critical patent/KR20240149982A/ko
Publication of KR20200014363A publication Critical patent/KR20200014363A/ko
Application granted granted Critical
Publication of KR102714702B1 publication Critical patent/KR102714702B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197038639A 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법 Active KR102714702B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247032911A KR20240149982A (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513831P 2017-06-01 2017-06-01
US62/513,831 2017-06-01
PCT/US2018/035670 WO2018223040A1 (en) 2017-06-01 2018-06-01 Methods of treating a tumor using an anti-pd-1 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032911A Division KR20240149982A (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20200014363A KR20200014363A (ko) 2020-02-10
KR102714702B1 true KR102714702B1 (ko) 2024-10-10

Family

ID=62685228

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197038639A Active KR102714702B1 (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법
KR1020247032911A Pending KR20240149982A (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247032911A Pending KR20240149982A (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Country Status (6)

Country Link
US (3) US11566073B2 (https=)
EP (1) EP3630840A1 (https=)
JP (3) JP7780857B2 (https=)
KR (2) KR102714702B1 (https=)
CN (2) CN117462668A (https=)
WO (1) WO2018223040A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
MA52789A (fr) * 2018-02-13 2021-04-14 Merck Sharp & Dohme Méthodes de traitement du cancer avec des anticorps anti-pd-1
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
AU2019403339A1 (en) * 2018-12-19 2021-07-08 Strata Oncology, Inc. Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer
CN114269376A (zh) * 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
US12275986B2 (en) * 2020-01-06 2025-04-15 Duke University Biomarkers associated with checkpoint immune therapy and methods of using same
CN110923329B (zh) * 2020-02-06 2020-05-12 至本医疗科技（上海）有限公司 Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN111440822A (zh) * 2020-04-16 2020-07-24 苏州大学附属第二医院 一种突变lats1质粒的构建与应用
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
CN112961920A (zh) * 2021-03-24 2021-06-15 臻和(北京)生物科技有限公司 一种预测肝胆肿瘤患者免疫检查点抑制剂联合靶向治疗疗效的方法及产品
JP7806990B2 (ja) * 2021-08-10 2026-01-27 国立大学法人 新潟大学 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法
CN113943806A (zh) * 2021-11-04 2022-01-18 至本医疗科技（上海）有限公司 预测肺腺癌患者对免疫疗法敏感性的生物标志物、应用和装置
WO2023209035A1 (en) * 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Methods and systems for predicting cancer therapy response
CN114931637B (zh) * 2022-06-27 2025-02-18 中山大学中山眼科中心 Pdl1抗体在角膜新生血管疾病中的应用
CN116449009A (zh) * 2023-01-30 2023-07-18 上海秤信生物科技有限公司 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物
WO2025085707A1 (en) * 2023-10-19 2025-04-24 Tesaro, Inc. Methods of treating cancer with anti-pd-1 agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
EP3916017A1 (en) 2014-12-22 2021-12-01 PD-1 Acquisition Group, LLC Anti-pd-1 antibodies
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
WO2016191751A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017040990A1 (en) * 2015-09-03 2017-03-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
MX2018007295A (es) 2016-01-11 2019-03-28 Armo Biosciences Inc Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos.
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN111491361B (zh) 2016-02-02 2023-10-24 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017210624A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
CN113249483B (zh) * 2021-06-10 2021-10-08 北京泛生子基因科技有限公司 一种检测肿瘤突变负荷的基因组合、系统及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Andreas H. Scheel, et al., Oncoimmunology, 2016, 5(5), e1131379.*
Luisa Carbognin, et al., PLoS ONE, 2015, 10(6), e0130142.*

Also Published As

Publication number Publication date
US20230279114A1 (en) 2023-09-07
JP2023159179A (ja) 2023-10-31
WO2018223040A1 (en) 2018-12-06
CN110678483B (zh) 2023-09-22
US20250145713A1 (en) 2025-05-08
US20200109204A1 (en) 2020-04-09
JP7780857B2 (ja) 2025-12-05
CN117462668A (zh) 2024-01-30
JP2020522508A (ja) 2020-07-30
JP2026053613A (ja) 2026-03-25
CN110678483A (zh) 2020-01-10
US11566073B2 (en) 2023-01-31
US12227576B2 (en) 2025-02-18
KR20240149982A (ko) 2024-10-15
KR20200014363A (ko) 2020-02-10
EP3630840A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
KR102714702B1 (ko) 항-pd-1 항체를 사용하여 종양을 치료하는 방법
US12466888B2 (en) Methods of treating tumor
KR102775647B1 (ko) 종양을 치료하는 방법
US20240190963A1 (en) Methods of treating tumor
US12479917B2 (en) Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20260042840A1 (en) Methods of treating tumor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601